Vortosiran for VTE Prevention
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.
Also called NCT07850453
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Registry
-
NCT07850453 -
2026-525479-15
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Bulgaria, France, Poland, Romania
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07850453. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2027-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vortosiran for VTE Prevention
- Condition
- Venous Thromboembolism (VTE)
- Condition
- Cancer
- Condition
- Pulmonary Embolism (Diagnosis)
- Intervention (Drug)
- Vortosiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ribocure Pharmaceuticals AB
- Collaborator
- Fortrea
Record details
- Record id
cardio:ct-nct07850453- Content hash
f7e4eed78443aace7d272f14687a53cd6db039b9c3ac5cc4802047ea8a951389